Summary

Types of mito, summary icon - DNA affected icon

Type of DNA affected

Mitochondrial

Types of mito, summary icon - Types of mito, summary icon - Genetic change icon

Common genetic change

m.3243A>G 

Types of mito, summary icon - Age of onset icon

Typical age of onset

2-40 years old

Types of mito, summary icon - Body area affected

Body area impacted

Brain and muscles

Summary

Types of mito, summary icon - DNA affected icon

Type of DNA affected

Mitochondrial

Types of mito, summary icon - Types of mito, summary icon - Genetic change icon

Common genetic change

m.3243A>G 

Types of mito, summary icon - Age of onset icon

Typical age of onset

2-40 years old

Types of mito, summary icon - Body area affected

Body area impacted

 Brain and muscles

Summary

Types of mito, summary icon - DNA affected icon

Type of DNA affected
Mitochondrial

Types of mito, summary icon - Types of mito, summary icon - Genetic change icon

Common genetic change
m.3243A>G 

Types of mito, summary icon - Age of onset icon

Age of onset
2-40 years old

Types of mito, summary icon - Body area affected

Body area impacted
Brain and muscles

About MELAS

Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes, most commonly known as MELAS, is a rare inherited genetic condition. It is one of at least 350 known types of mitochondrial disease (mito).

Mito affects the mitochondria, which are tiny parts inside our cells that help make the energy our bodies need. When mitochondria do not work as they should, some parts of the body may not have enough energy to work properly. MELAS is a condition that affects many parts of the body and tends to get worse over time. It most often affects the brain, muscles, endocrine (the body’s hormone) system, hearing, vision, and the heart.1–4

The onset of MELAS usually occurs between the ages of 2 and 40,4,5 but onset can occur at any age, including late adulthood.1,6–8 Signs and symptoms may include stroke-like episodes with seizures, changes in behaviour, motor issues such as a loss of balance, and visual and or hearing impairments.1,4

Prefer to listen?

Hear this information on our Audio Learning Channel.

Curious about mito?

For more information visit our Understanding mito page. You’ll find explanations about what mito is, its symptoms, its causes, and how it affects the body.

Speech bubble icon

Pronunciation

Mitochondrial (Mai-tuh-kon-dree-uhl) Encephalopathy (en-seh-fuh-lo-puh-thee), Lactic Acidosis, and Stroke-like episodes.

MELAS (ME-LAS)

Clipboard icon

Other names for MELAS

  • Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, Stroke-like
  • Myopathy, Mitochondrial-Encephalopathy-Lactic Acidosis-Stroke

MELAS may also be referred to as:

  • Mitochondrial disease (mito)
  • Primary mitochondrial disease (PMD)
  • Mitochondrial encephalomyopathy
Emergency ambulance icon

Planning for urgent care

If your mito specialist thinks you may get unwell quickly, they may give you an emergency plan. If you do not have a mito specialist, you could ask the specialist you see who knows about mito.

An emergency plan lists your diagnosis and care information from your care team. It can help to keep a copy with you. This could be on paper, on your phone or saved where you or your carer can find it fast. You can show the plan if you go to hospital, need an ambulance or see a new health professional. It can also help to keep current contact details for your main care team. This may include your general practitioner (GP), mito specialist or other specialist. You can also list other health professionals who know you well.

The Australian Patient Care Standards for mito and Important information about medicines can also help guide health professionals who are less familiar with mito.

Mito Foundation Awards - Shelley (1)

Hi. I'm Shelley.

"Mitochondrial disease is part of my life and my family’s story. I manage health challenges with the support of a great medical team. I’m focused on the future and exploring safe ways to have a child, including mitochondrial donation. I carry my mum and brother’s strength with me every day."

Beyond the basics

Learn more and find support to help you navigate your journey with mito.

Flag Icon Milestones

1984 – First description

MELAS was first described by Dr Pavlakis and his team. They found a group of people with similar symptoms, now known as MELAS.9 It was also one of the first types of mito linked to changes in mitochondrial DNA (mtDNA).10 

1990 – Genetic discovery

Researchers found the most common genetic change linked to MELAS: m.3243A>G in the MT-TL1 gene (part of mitochondrial DNA). This helped scientists better understand the genetic causes of mitochondrial disease.11

Early 2000s – New treatment approach

L-arginine began to be used around 2002 to help manage stroke-like episodes in people with MELAS. Early reports suggested it might improve blood flow in the brain during these episodes. More formal studies and wider use followed in the late 2000s.12–14

2010s to now – Ongoing research

Research continues into better treatments and ways to manage symptoms. Scientists are also studying other genetic changes linked to MELAS and testing therapies like antioxidants in clinical trials.

Globe Icon Prevalence
Symptoms Icon Symptoms
Flag Icon Causes
Diagnosis Icon Diagnosis
Care team Icon Care team
Health care Icon Health care
Clinical studies Icon Clinical studies
Support Icon Support groups

Mito Foundation support services

Helpline

Call Helpine for general advice, assistance in seeking a referral or more information on Mito Foundation support services.

Events

Mito Foundation events bring together people impacted by mitochondrial disease (mito).

NDIS support

Access the NDIS Navigation Service (NNS) for resources, education and 1:1 guidance on the NDIS.

Disclaimer: Resources provided by the Australian Mitochondrial Disease Foundation Limited (Mito Foundation), offers general information and is not a substitute for medical advice. It is essential to assess the suitability of the content for your individual circumstances and make decisions based on your medical condition. The information’s accuracy is subject to change, and we do not guarantee ongoing currency or availability. While efforts are made to ensure accuracy, Mito Foundation is not obligated to provide updated information. The copyright for this document and its content belongs to, or is licensed to, Mito Foundation, and reproduction without prior written consent is prohibited.

Acknowledgement: Mito Foundation acknowledges the valuable contributions of our reviewers, we thank Professor John Christodoulou AM MB BS PhD FRACP FRCPA FHGSA, and Dr Benjamin Kamien (Clinical Geneticist), for their review. As well as members of the mito community resource review panel.

Author: Mito Foundation 
Version: 1
Date published: Wednesday 6 August 2025